Skip to content

Hemodynamic response assessed by the *HandScan* in hand and wrist joints of patients with osteoarthritis compared to patients with rheumatoid arthritis

Hemodynamic response assessed by the *HandScan* in hand and wrist joints of patients with osteoarthritis compared to patients with rheumatoid arthritis - HandScan hemodynamic response,OA compared to RA; a pilot

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON44590
Enrollment
100
Registered
2016-08-01
Start date
2015-05-19
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

'OA' Osteoarthritis 'RA' Rheumatoid Arthritis

Interventions

Per patient a HandScan measurement, an US of hands and wrists and physical examination is performed.
HandScan
Osteoarthritis
Rheumatoid Arthritis

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: * Diagnosed with Rheumatoid Arthritis according to ACR/EULAR 2010 criteria or with OsteoArthritis according to ACR 1990 criteria. * Age between 18 and 90 years * * 1 swollen hand joints * Ability to give informed consent

Exclusion criteria

Exclusion criteria: * Other diagnosis than OA or RA that can explain pain or swelling in the hand joints, such as other inflammatory rheumatic diseases (psoriatic arthritis, gout). * Intra-articular treatment with steroid injection within 3 months of assessments of the joints * Trauma or surgery of one of the hand joints within 6 months of assessments of the joints * Light sensitivity, i.e. Erythropoietic protoporphyria or patients on photodynamic therapy * Artificial joints of wrist/hand

Design outcomes

Primary

MeasureTime frame
* Hemodynamic response, as provided standard by the HandScan (continuous value, 0-3 per joint). * Inflammation defined by US: Gray scale (0-3 per joint) and Power Doppler (0-3 per joint)

Secondary

MeasureTime frame
Difference in disease characteristics detectable by US; bone osteophytes (0-1), tenosynovitis (0-1).

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)